Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100Q645
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥36.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥38.3bnat 2022-12-31Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥38.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥13.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.322021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.082021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥241.232021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥279m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥11m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥770m
—segment totalrevenue2021-04-01 → 2021-12-31¥36.5bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥36.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥12m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 355
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member757900
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0672
Number of shares held in own name treasury shares etcCurrentQuarterInstant757900
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant757900
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0672
Cash and depositsPrior1YearInstant10643000000JPY
Cash and depositsCurrentQuarterInstant10026000000JPY
Notes and accounts receivable tradePrior1YearInstant7870000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant6729000000JPY
Merchandise and finished goodsPrior1YearInstant1020000000JPY
Merchandise and finished goodsCurrentQuarterInstant1381000000JPY
Work in processPrior1YearInstant70000000JPY
Work in processCurrentQuarterInstant64000000JPY
Raw materials and suppliesPrior1YearInstant760000000JPY
Raw materials and suppliesCurrentQuarterInstant654000000JPY
Other caPrior1YearInstant2304000000JPY
Other caCurrentQuarterInstant1939000000JPY
Allowance for doubtful accounts caPrior1YearInstant-1000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-1000000JPY
Current assetsPrior1YearInstant22668000000JPY
Current assetsCurrentQuarterInstant20795000000JPY
Buildings and structuresPrior1YearInstant8586000000JPY
Buildings and structuresCurrentQuarterInstant9401000000JPY
Accumulated depreciation buildings and structuresPrior1YearInstant-4471000000JPY
Accumulated depreciation buildings and structuresCurrentQuarterInstant-4684000000JPY
Buildings and structures netPrior1YearInstant4114000000JPY
Buildings and structures netCurrentQuarterInstant4717000000JPY
LandPrior1YearInstant4589000000JPY
LandCurrentQuarterInstant4554000000JPY
Lease assets ppePrior1YearInstant1328000000JPY
Lease assets ppeCurrentQuarterInstant1286000000JPY
Accumulated depreciation lease assets ppePrior1YearInstant-721000000JPY
Accumulated depreciation lease assets ppeCurrentQuarterInstant-848000000JPY
Lease assets net ppePrior1YearInstant607000000JPY
Lease assets net ppeCurrentQuarterInstant437000000JPY
Other ppePrior1YearInstant5034000000JPY
Other ppeCurrentQuarterInstant4377000000JPY
Accumulated depreciation other ppePrior1YearInstant-3687000000JPY
Accumulated depreciation other ppeCurrentQuarterInstant-3589000000JPY
Other net ppePrior1YearInstant1346000000JPY
Other net ppeCurrentQuarterInstant788000000JPY
Property plant and equipmentPrior1YearInstant10658000000JPY
Property plant and equipmentCurrentQuarterInstant10497000000JPY
GoodwillPrior1YearInstant28000000JPY
GoodwillCurrentQuarterInstant16000000JPY
Other iaPrior1YearInstant466000000JPY
Other iaCurrentQuarterInstant373000000JPY
Intangible assetsPrior1YearInstant495000000JPY
Intangible assetsCurrentQuarterInstant389000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass